Singulair and Biktarvy drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Singulair (montelukast sodium) and Biktarvy (bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate). Common drug interactions include lower limb fracture among females and emotional distress among males.

The phase IV clinical study analyzes what interactions people have when they take Singulair and Biktarvy. It is created by eHealthMe based on reports of 56 people who take the same drugs from the FDA, and is updated regularly.

What is Singulair?

Singulair has active ingredients of montelukast sodium. It is often used in asthma. eHealthMe is studying from 129,752 Singulair users. Check the latest studies of Singulair.

What is Biktarvy?

Biktarvy has active ingredients of bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate. It is often used in hiv infection. eHealthMe is studying from 19,543 Biktarvy users. Check the latest studies of Biktarvy.



On Jul, 08, 2026

56 people who take Singulair and Biktarvy together, and have interactions are studied.

Singulair and Biktarvy drug interactions.

What are the common drug interactions of Singulair and Biktarvy, by gender? *:

female:

  1. Lower limb fracture
  2. Neck pain
  3. Osteomalacia (softening of the bones due to a lack of vitamin d)
  4. Pain in extremity
  5. Proteinuria (presence of protein in the urine)
  6. Renal failure (kidney dysfunction)
  7. Alopecia (absence of hair from areas of the body)
  8. Bone disorder
  9. Cervical vertebral fracture
  10. Death

male:

  1. Emotional distress
  2. Pain
  3. Loss of consciousness
  4. Mastoiditis (infection of mastoid bone)
  5. Multiple fractures
  6. Osteonecrosis (death of bone)
  7. Renal impairment (severely reduced kidney function)
  8. Foot fracture
  9. Hand fracture
  10. Osteopenia (a condition where bone mineral density is lower than normal)

What are the common drug interactions of Singulair and Biktarvy, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Alopecia (absence of hair from areas of the body)
  2. Anal abscess
  3. Impetigo (contagious skin infection)
  4. Nausea (feeling of having an urge to vomit)
  5. Sleep disorder

30-39:

  1. Osteoporosis (bones weak and more likely to break)
  2. Proteinuria (presence of protein in the urine)
  3. Bone density decreased
  4. Emotional distress
  5. Pain
  6. Depression
  7. Anhedonia (inability to experience pleasure from activities usually found enjoyable)
  8. Anxiety
  9. Chronic kidney disease
  10. Bone loss

40-49:

n/a

50-59:

  1. Emotional distress
  2. Pain
  3. Anhedonia (inability to experience pleasure from activities usually found enjoyable)
  4. Anxiety
  5. Osteopenia (a condition where bone mineral density is lower than normal)
  6. Chronic kidney disease
  7. Multiple fractures
  8. Osteoporosis (bones weak and more likely to break)
  9. Bone density decreased
  10. Depression

60+:

  1. Arthralgia (joint pain)
  2. Pruritus (severe itching of the skin)
  3. Musculoskeletal stiffness (stiffness of the body's muscles, joints, tendons, ligaments and nerves)
  4. Speech disorder
  5. Adverse event
  6. Balance disorder
  7. Confusional state
  8. Diarrhoea
  9. Dizziness
  10. Fear

What are the existing conditions these people have? *

  1. Depression: 10 people, 17.86%
  2. Insomnia (sleeplessness): 10 people, 17.86%
  3. High Blood Pressure: 9 people, 16.07%
  4. Irritable Bowel Syndrome: 7 people, 12.50%
  5. Arthritis (form of joint disorder that involves inflammation of one or more joints): 7 people, 12.50%
  6. Psoriasis (immune-mediated disease that affects the skin): 6 people, 10.71%
  7. High Blood Cholesterol: 6 people, 10.71%
  8. Pain: 6 people, 10.71%
  9. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 6 people, 10.71%
  10. Fungal Infection: 6 people, 10.71%

* Approximation only. Some reports may have incomplete information.

Do you take Singulair and Biktarvy?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Singulair and Biktarvy:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Singulair:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Biktarvy:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Singulair and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Biktarvy and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on montelukast sodium and bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate (the active ingredients of Singulair and Biktarvy, respectively), and Singulair and Biktarvy (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: